Literature DB >> 1382457

High level expression on a chimeric anti-ganglioside GD2 antibody: genomic kappa sequences improve expression in COS and CHO cells.

L A Fouser1, S L Swanberg, B Y Lin, M Benedict, K Kelleher, D A Cumming, G E Riedel.   

Abstract

We report a flexible strategy for the high level expression of a recombinant human monoclonal antibody (mAb) in Chinese hamster ovary (CHO) cells, initially using COS monkey kidney cell transfections to evaluate rapidly modifications to immunoglobulin (Ig) DNA constructs. Using sequential transfections with two amplifiable markers, we generated CHO cell lines and clones that secrete 80-110 micrograms/10(6) cells/24 hours of a mouse-human chimeric IgG1 kappa mAb. This cellular productivity is considerably greater than most murine hybridomas and transfected myelomas. Our data also demonstrate that genomic kappa sequences can improve mAb expression in COS and CHO cells. As a paradigm, we focused our expression studies on a human chimeric form of 3F8, a murine mAb that binds to ganglioside GD2 on neuroblastoma and melanoma tumor cells.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1382457     DOI: 10.1038/nbt1092-1121

Source DB:  PubMed          Journal:  Biotechnology (N Y)        ISSN: 0733-222X


  3 in total

Review 1.  Generation of recombinant antibodies.

Authors:  S M Kipriyanov; M Little
Journal:  Mol Biotechnol       Date:  1999-09       Impact factor: 2.695

2.  In vitro comparison of the antigen-binding and stability properties of the various molecular forms of IgA antibodies assembled and produced in CHO cells.

Authors:  J Berdoz; C T Blanc; M Reinhardt; J P Kraehenbuhl; B Corthésy
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-16       Impact factor: 11.205

3.  A quick and efficient system for antibiotic-free expression of heterologous genes in tobacco roots.

Authors:  S Komarnytsky; A Gaume; A Garvey; N Borisjuk; I Raskin
Journal:  Plant Cell Rep       Date:  2004-02-10       Impact factor: 4.570

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.